{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:34:54Z","timestamp":1768008894362,"version":"3.49.0"},"reference-count":58,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"JSPS KAKENHI","award":["17K09881"],"award-info":[{"award-number":["17K09881"]}]},{"name":"JSPS KAKENHI","award":["20K17508"],"award-info":[{"award-number":["20K17508"]}]},{"name":"JSPS KAKENHI","award":["23K15411"],"award-info":[{"award-number":["23K15411"]}]},{"DOI":"10.13039\/100008695","name":"Japan Foundation for Applied Enzymology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008695","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>C-type natriuretic peptide (CNP) plays a crucial role in enhancing endochondral bone growth and holds promise as a therapeutic agent for impaired skeletal growth. To overcome CNP's short half-life, we explored the potential of dampening its clearance system. Neprilysin (NEP) is an endopeptidase responsible for catalyzing the degradation of CNP. Thus, we investigated the effects of NEP inhibition on skeletal growth by administering sacubitril, a NEP inhibitor, to C57BL\/6 mice. Remarkably, we observed a dose-dependent skeletal overgrowth phenotype in mice treated with sacubitril. Histological analysis of the growth plate revealed a thickening of the hypertrophic and proliferative zones, mirroring the changes induced by CNP administration. The promotion of skeletal growth observed in wild-type mice treated with sacubitril was nullified by the knockout of cartilage-specific natriuretic peptide receptor B (NPR-B). Notably, sacubitril promoted skeletal growth in mice only at 3 to 4 weeks of age, a period when endogenous CNP and NEP expression was higher in the lumbar vertebrae. Additionally, sacubitril facilitated endochondral bone growth in organ culture experiments using tibial explants from fetal mice. These findings suggest that NEP inhibition significantly promotes skeletal growth via the CNP\/NPR-B pathway, warranting further investigations for potential applications in people with short stature.<\/jats:p>","DOI":"10.1210\/endocr\/bqae058","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:28:45Z","timestamp":1715783325000},"source":"Crossref","is-referenced-by-count":5,"title":["Neprilysin Inhibition Promotes Skeletal Growth via the CNP\/NPR-B Pathway"],"prefix":"10.1210","volume":"165","author":[{"given":"Takuro","family":"Hakata","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-2784","authenticated-orcid":false,"given":"Yohei","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-4231","authenticated-orcid":false,"given":"Takafumi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Metabolism and Endocrinology Division of Internal Medicine, Kishiwada City Hospital , Osaka 596-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-502X","authenticated-orcid":false,"given":"Ichiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Sugawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0254-6974","authenticated-orcid":false,"given":"Toshihito","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Taura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Yasoda","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center , Kyoto 612-8555 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine \u00a0 Gifu 501-1194 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-2593","authenticated-orcid":false,"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507 , Japan"},{"name":"Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai , Osaka 530-8480 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"2","key":"2024070101464140300_bqae058-B1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"2024070101464140300_bqae058-B2","first-page":"907","article-title":"Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides","volume":"10","author":"Nakao","year":"1992","journal-title":"J Hypertens"},{"issue":"49","key":"2024070101464140300_bqae058-B3","doi-asserted-by":"crossref","first-page":"17300","DOI":"10.1073\/pnas.0407894101","article-title":"Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs","volume":"101","author":"Tamura","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024070101464140300_bqae058-B4","doi-asserted-by":"crossref","first-page":"e0194812","DOI":"10.1371\/journal.pone.0194812","article-title":"Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death","volume":"13","author":"Fujii","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"2024070101464140300_bqae058-B5","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1073\/pnas.071389098","article-title":"Dwarfism and early death in mice lacking C-type natriuretic peptide","volume":"98","author":"Chusho","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024070101464140300_bqae058-B6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat Med"},{"issue":"6","key":"2024070101464140300_bqae058-B7","doi-asserted-by":"crossref","first-page":"E1339","DOI":"10.1152\/ajpendo.00272.2009","article-title":"Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice","volume":"297","author":"Kake","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2024070101464140300_bqae058-B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/422013","article-title":"Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux","volume":"75","author":"Bartels","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2024070101464140300_bqae058-B9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1210\/jc.2005-1949","article-title":"Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature","volume":"91","author":"Olney","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024070101464140300_bqae058-B10","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1210\/jc.2007-1101","article-title":"Intact kinase homology domain of natriuretic peptide receptor-B is essential for skeletal development","volume":"92","author":"Hachiya","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024070101464140300_bqae058-B11","doi-asserted-by":"crossref","first-page":"E1636","DOI":"10.1210\/jc.2013-2142","article-title":"Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature","volume":"98","author":"Vasques","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024070101464140300_bqae058-B12","doi-asserted-by":"crossref","first-page":"E713","DOI":"10.1210\/jc.2013-3525","article-title":"Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature","volume":"99","author":"Amano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024070101464140300_bqae058-B13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/gim.2017.66","article-title":"Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature","volume":"20","author":"Hisado-Oliva","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"2024070101464140300_bqae058-B14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajmg.a.37463","article-title":"Acromesomelic dysplasia, type maroteaux caused by novel loss-of-function mutations of the NPR2 gene: three case reports","volume":"170A","author":"Wang","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"7","key":"2024070101464140300_bqae058-B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/humu.20511","article-title":"Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation","volume":"28","author":"Bocciardi","year":"2007","journal-title":"Hum Mutat"},{"issue":"8","key":"2024070101464140300_bqae058-B16","doi-asserted-by":"crossref","first-page":"e42180","DOI":"10.1371\/journal.pone.0042180","article-title":"An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene","volume":"7","author":"Miura","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"2024070101464140300_bqae058-B17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2013.06.024","article-title":"A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B","volume":"56","author":"Robinson","year":"2013","journal-title":"Bone"},{"issue":"5","key":"2024070101464140300_bqae058-B18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/ajmg.a.36884","article-title":"Skeletal overgrowth syndrome caused by overexpression of C-type natriuretic peptide in a girl with balanced chromosomal translocation, t(1;2)(q41;q37.1)","volume":"167A","author":"Ko","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"12","key":"2024070101464140300_bqae058-B19","doi-asserted-by":"crossref","first-page":"E1988","DOI":"10.1210\/jc.2013-2358","article-title":"An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities","volume":"98","author":"Hannema","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024070101464140300_bqae058-B20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajmg.a.36218","article-title":"Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene","volume":"164A","author":"Miura","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"7","key":"2024070101464140300_bqae058-B21","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/en.2008-1676","article-title":"Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias","volume":"150","author":"Yasoda","year":"2009","journal-title":"Endocrinology"},{"issue":"7","key":"2024070101464140300_bqae058-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"issue":"10252","key":"2024070101464140300_bqae058-B23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2024070101464140300_bqae058-B24","doi-asserted-by":"crossref","first-page":"bqaa008","DOI":"10.1210\/endocr\/bqaa008","article-title":"C-Type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII","volume":"161","author":"Yamashita","year":"2020","journal-title":"Endocrinology"},{"issue":"11","key":"2024070101464140300_bqae058-B25","doi-asserted-by":"crossref","first-page":"e0277140","DOI":"10.1371\/journal.pone.0277140","article-title":"Circulatory C-type natriuretic peptide reduces mucopolysaccharidosis-associated craniofacial hypoplasia in vivo","volume":"17","author":"Kashiwagi","year":"2022","journal-title":"PLoS One"},{"key":"2024070101464140300_bqae058-B26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bone.2016.08.026","article-title":"C-type natriuretic peptide restores impaired skeletal growth in a murine model of glucocorticoid-induced growth retardation","volume":"92","author":"Ueda","year":"2016","journal-title":"Bone"},{"issue":"1","key":"2024070101464140300_bqae058-B27","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1038\/s41598-019-44975-w","article-title":"Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment","volume":"9","author":"Ueda","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"2024070101464140300_bqae058-B28","first-page":"1428","article-title":"Bioactivity and metabolism of C-type natriuretic peptide in normal man","volume":"78","author":"Hunt","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Pt 2","key":"2024070101464140300_bqae058-B29","first-page":"R201","article-title":"Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep","volume":"268","author":"Charles","year":"1995","journal-title":"Am J Physiol"},{"issue":"7","key":"2024070101464140300_bqae058-B30","first-page":"986","article-title":"CNP, the third natriuretic peptide: its biology and significance to the cardiovascular system","volume":"11","author":"Nakagawa","year":"2022","journal-title":"Biology (Basel)"},{"issue":"11","key":"2024070101464140300_bqae058-B31","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J"},{"issue":"11","key":"2024070101464140300_bqae058-B32","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1172\/JCI94912","article-title":"Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance","volume":"127","author":"Kanai","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"2024070101464140300_bqae058-B33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"2024070101464140300_bqae058-B34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/clinchem\/hvac005","article-title":"Circulating concentrations of C-type natriuretic peptides increase with sacubitril\/valsartan treatment in healthy young men","volume":"68","author":"Thonsgaard","year":"2022","journal-title":"Clin Chem"},{"issue":"2 Pt 1","key":"2024070101464140300_bqae058-B35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/01.HYP.30.2.184","article-title":"Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo","volume":"30","author":"Brandt","year":"1997","journal-title":"Hypertension"},{"issue":"11","key":"2024070101464140300_bqae058-B36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2024070101464140300_bqae058-B37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41569-019-0282-2","article-title":"Mechanisms of sacubitril\u2013valsartan benefit in HFrEF","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2024070101464140300_bqae058-B38","doi-asserted-by":"crossref","first-page":"10554","DOI":"10.1038\/srep10554","article-title":"The Local CNP\/GC-B system in growth plate is responsible for physiological endochondral bone growth","volume":"5","author":"Nakao","year":"2015","journal-title":"Sci Rep"},{"issue":"9","key":"2024070101464140300_bqae058-B39","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1101\/gad.1171104","article-title":"Interactions between Sox9 and beta-catenin control chondrocyte differentiation","volume":"18","author":"Akiyama","year":"2004","journal-title":"Genes Dev"},{"issue":"9","key":"2024070101464140300_bqae058-B40","doi-asserted-by":"crossref","first-page":"e0204172","DOI":"10.1371\/journal.pone.0204172","article-title":"Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats","volume":"13","author":"Hirota","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"2024070101464140300_bqae058-B41","doi-asserted-by":"crossref","first-page":"e006617","DOI":"10.1161\/JAHA.117.006617","article-title":"Angiotensin II receptor-neprilysin inhibitor sacubitril\/valsartan improves endothelial dysfunction in spontaneously hypertensive rats","volume":"6","author":"Seki","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2024070101464140300_bqae058-B42","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/ndt\/gfad098","article-title":"Sacubitril\/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess","volume":"38","author":"Nishio","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2024070101464140300_bqae058-B43","doi-asserted-by":"crossref","first-page":"bqac005","DOI":"10.1210\/endocr\/bqac005","article-title":"C-type natriuretic peptide\u2013induced PKA activation promotes endochondral bone formation in hypertrophic chondrocytes","volume":"163","author":"Hirota","year":"2022","journal-title":"Endocrinology"},{"issue":"8","key":"2024070101464140300_bqae058-B44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm0897-904","article-title":"The control of microvascular permeability and blood pressure by neutral endopeptidase","volume":"3","author":"Lu","year":"1997","journal-title":"Nat Med"},{"issue":"3","key":"2024070101464140300_bqae058-B45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12031-010-9460-8","article-title":"Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP\/NEP2-deficient mice","volume":"43","author":"Hanson","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"4","key":"2024070101464140300_bqae058-B46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3233\/JAD-142463","article-title":"Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease","volume":"44","author":"H\u00fcttenrauch","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2024070101464140300_bqae058-B47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajpath.2010.11.012","article-title":"Neprilysin-2 is an important \u03b2-amyloid degrading enzyme","volume":"178","author":"Hafez","year":"2011","journal-title":"Am J Pathol"},{"issue":"9","key":"2024070101464140300_bqae058-B48","doi-asserted-by":"crossref","first-page":"e12793","DOI":"10.1371\/journal.pone.0012793","article-title":"New function for an old enzyme: NEP deficient mice develop late-onset obesity","volume":"5","author":"Becker","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"2024070101464140300_bqae058-B49","doi-asserted-by":"crossref","first-page":"E307","DOI":"10.1152\/ajpendo.00234.2021","article-title":"Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with \u03b2-cell dysfunction","volume":"322","author":"Esser","year":"2022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"2024070101464140300_bqae058-B50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2024070101464140300_bqae058-B51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0006-2952(90)90012-A","article-title":"Characterization of endopeptidase 3.4.24.11 (\u201cenkephalinase\u201d) activity in human plasma and cerebrospinal fluid","volume":"39","author":"Spillantini","year":"1990","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2024070101464140300_bqae058-B52","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/clinchem\/38.9.1785","article-title":"Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors","volume":"38","author":"Yandle","year":"1992","journal-title":"Clin Chem"},{"issue":"10","key":"2024070101464140300_bqae058-B53","doi-asserted-by":"crossref","first-page":"e0240023","DOI":"10.1371\/journal.pone.0240023","article-title":"Is C-type natriuretic peptide regulated by a feedback loop? A study on systemic and local autoregulatory effect","volume":"15","author":"Ueda","year":"2020","journal-title":"PLoS One"},{"key":"2024070101464140300_bqae058-B54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ghir.2018.12.004","article-title":"Growth hormone therapy in children; research and practice\u2014a review","volume":"44","author":"Collett-Solberg","year":"2019","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2024070101464140300_bqae058-B55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.beem.2015.04.009","article-title":"Hormone replacement therapy in children: the use of growth hormone and IGF-I","volume":"29","author":"Pf\u00e4ffle","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9722","key":"2024070101464140300_bqae058-B56","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2024070101464140300_bqae058-B57","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1111\/cns.14195","article-title":"Updated insights on dementia-related risk of sacubitril\/valsartan: a real-world pharmacovigilance analysis","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"2024070101464140300_bqae058-B58","doi-asserted-by":"crossref","first-page":"940654","DOI":"10.3389\/fendo.2022.940654","article-title":"Effects of sacubitril\/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction","volume":"13","author":"Cloro","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae058\/57700997\/bqae058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/7\/bqae058\/58358542\/bqae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/7\/bqae058\/58358542\/bqae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:47:10Z","timestamp":1719798430000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae058\/7675050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,5,27]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae058","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,16]]},"article-number":"bqae058"}}